Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : LongeVC
Deal Size : Undisclosed
Deal Type : Financing
LongeVC Joins Freedom Biosciences’ Funding Round for Psychedelic-Powered Mental Health Care
Details : The net proceeds will be used by the company to focus on its FREE001, a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.
Product Name : FREE001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 14, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : LongeVC
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : MBX Capital
Deal Size : $10.5 million
Deal Type : Financing
Details : The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory programs. Program FREE001 is a ketamine treatment that’s been demonstrated in clinical trials to have more durable effe...
Product Name : FREE001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 23, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : MBX Capital
Deal Size : $10.5 million
Deal Type : Financing
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : MBX Capital
Deal Size : $10.5 million
Deal Type : Financing
Details : The company will use the net proceeds to focus on its FREE001, a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.
Product Name : FREE001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 23, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : MBX Capital
Deal Size : $10.5 million
Deal Type : Financing